Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)

被引：0

作者：

Normanno, N. ^{[1
]}

Rachiglio, A. M. ^{[1
]}

Abate, R. Esposito ^{[1
]}

Orlandi, A. ^{[2
]}

Maiello, E. ^{[3
]}

Maglietta, G. ^{[4
,5
]}

Damato, A. ^{[3
]}

Maiello, M. R. ^{[1
]}

Carotenuto, M. ^{[1
]}

Calegari, M. A. ^{[2
]}

Antonuzzo, L. ^{[6
]}

Bordonaro, R. ^{[7
]}

Zampino, M. G. ^{[8
]}

Tamberi, S.

Lonardi, S. ^{[9
]}

Avallone, A. ^{[10
]}

Latiano, T. P. ^{[3
]}

Tamburini, E. ^{[11
]}

Barone, C. A. ^{[2
]}

Pinto, C.

机构：

[1] Ist Nazl Tumori IRCCS Fondazione G Pascale, Translat Res Dept, Naples, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Dept, Rome, Italy

[3] Med Oncol, IRCCS Fdn Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy

[4] Azienda Osped Univ Parma, Clin & Epidemiol Res Unit, Parma, Italy

[5] IRCCS, Azienda Osped Arcispedale Santa Maria Nuov, Reggio Emilia, Italy

[6] AOUC, Med Oncol Dept, Florence, Italy

[7] Dept Oncol, Azienda Osped ARNAS Garibaldi, Catania, Italy

[8] Osped Santa Maria Croci, Med Oncol, Ravenna, Italy

[9] IRCCS, Dept Oncol, IOV Ist Oncol Veneto, Padua, Italy

[10] IRCCS Fdn G Pascale, Ist Nazl Tumori, Abdominal Oncol Dept, Naples, Italy

[11] Azienda Osped Cardinale Giovanni Panico, Med Oncol, Tricase, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.122

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

111P

引用

页码：S52 / S52

页数：1

共 50 条

[41] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
Beslija, S.
Koza, I.
Ocvirk, J.
Ciuleanu, T.
Kurteva, G.
Papamichael, D.
Vrbanec, D.
Messinger, D.
Brodowicz, T.
Zielinski, C. C.
ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
[42] Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID)
Arai, Hiroyuki
Tsuda, Takashi
Sunakawa, Yu
Shimokawa, Mototsugu
Akiyoshi, Kohei
Tokunaga, Shinya
Shoji, Hirokazu
Kunieda, Kenji
Kotaka, Masahito
Matsumoto, Toshihiko
Nagata, Yusuke
Mizukami, Takuro
Mizuki, Fumitaka
Danenberg, Kathleen D.
Boku, Narikazu
Nakajima, Takako Eguchi
CANCER MEDICINE, 2024, 13 (07):
[43] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
Baron, A. D.
O'Bryant, C. L.
Choi, Y.
Ashkenazi, A.
Royer-Joo, S.
Portera, C. C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[44] Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)
Sorah, Jonathan D.
Moore, Dominic T.
Reilley, Matthew
Salem, Mohamed E.
Sanoff, Hanna Kelly
Triglianos, Tammy
McRee, Autumn Jackson
Lee, Michael Sangmin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[45] Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
Qin, Shukui
Guo, Weijian
Xu, Jian-Ming
Li, Qi
Cheng, Ying
Liu, Tian Shu
Chen, Jiongjie
Chen, Wen-Feng
Li, Jin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[46] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.
Antoniotti, Carlotta
Cremolini, Chiara
Loupakis, Fotios
Bergamo, Francesca
Grande, Roberta
Tonini, Giuseppe
Garattini, Silvio Ken
Masi, Gianluca
Battaglin, Francesca
Lucchesi, Sara
Salvatore, Lisa
Corsi, Domenico C.
Di Fabio, Francesca
Banzi, Maria
Sensi, Elisa
Tomcikova, Daniela
Fontanini, Gabriell
Zagonel, Vittorina
Boni, Luca
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[47] Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study
Damato, Angela
Damato, Angela
Aschele, Carlo
Ciardiello, Fortunato
Maiello, Evaristo
Siena, Salvatore
Torri, Valter
Dolcini, Virginia
Gervasi, Erika
La Grotteria, Ilenia
De Simone, Irene
Normanno, Nicola
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study
Stintzing, Sebastian
van Oostrum, Ilse
Pescott, Chris
Steinbach-Buechert, Alma Katharina
Heeg, Bart
Heinemann, Volker
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[49] FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
Personeni, Nicola
Rimassa, Lorenza
Verusio, Claudio
Barni, Sandro
Rubino, Luca
Bozzarelli, Silvia
Villa, Eugenio
Carnaghi, Carlo
Tronconi, Maria Chiara
Gerardi, Chiara
Galli, Francesca
Floriani, Irene
Destro, Annarita
Raschioni, Carlotta
Labianca, Roberto
Santoro, Armando
CLINICAL COLORECTAL CANCER, 2015, 14 (03) : 162 - 169
[50] Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
Liu, T.
Li, J.
Xu, J.
Wang, L.
Cheng, Y.
Chen, W.
Chen, J.
Pescott, C. P.
Qin, S.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →